A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D – MK-3475-06D
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Pietrantonio Filippo
Main Facility: Oncologia Medica Gastroenterologica
Drug: MK-2870 (experimental drug) or MK-1022 (experimental drug)
Pathologies: Esophageal tumors
ClinicalTrials.gov: Read the details about clinical trials
The study enrolls patients with advanced/metastatic gastroesophageal adenocarcinoma, in second-line with the possibility, based on a 1:1:1 randomization, of three different treatments:
- Arm 1: Ramucirumab + Paclitaxel
- Arm 2: MK 2870 + Paclitaxel
- Arm 3: MK1022 + Ramucirumab
The primary objective is to evaluate the ORR (objective response), that is the number of subjects whose tumor responds (shrinks or disappears) with the treatment.
Last update: 16/07/2026